查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1627676

人类胰岛素市场：未来预测（2025-2030）

Human Insulin Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

人类胰岛素市场预计将以 3.28% 的复合年增长率成长，到 2025 年市场规模将达到 233.3445 亿美元，到 2030 年将达到 274.2171 亿美元。

胰岛素是一种控制体内糖水平的荷尔蒙。糖尿病是一种慢性代谢疾病，涉及血糖值或糖水平异常升高。目前，糖尿病有两种类型：在第 1 型糖尿病中，胰臟中的 β 细胞停止分泌胰岛素；而在第 2 型糖尿病中，身体细胞对胰岛素分泌的敏感度降低。随着久坐生活方式的增加，胰岛素市场的糖尿病盛行率预计将飙升。此外，新兴国家良好的报销趋势也有望促进整体市场的成长。

人类胰岛素市场驱动因素

  • 糖尿病患者数量的增加将促进人类胰岛素市场的成长

糖尿病是一种慢性代谢疾病，其特征是低血糖导致血糖值升高。糖尿病是一种慢性代谢疾病，其中血糖浓度升高会导致低血糖。人类拥有人类胰岛素，广泛用于个人化治疗、临床照护中的胰岛素替代以及治疗和控制疾病的专科疗法。然而，治疗第 1 型糖尿病的药物消耗量不断增加进一步推动了对胰岛素的需求，这些药物透过提供人体无法形成的必需胰岛素来控制血糖值并预防高血糖。它是口服的，旨在改善葡萄糖的吸收并增加体内的胰岛素量。

此外，由于对胰岛素帮浦治疗产品的需求不断增加，市场也不断扩大，这种产品模仿健康胰臟的基础胰岛素分泌，并全天持续供应胰岛素。此外，人体胰岛素对于预防术前和重症加护环境中的高血糖和低血糖变化也至关重要，因此对于减少手术併发症至关重要。

人类胰岛素市场的地理展望：

  • 预测期内，北美将呈现指数级成长。

由于久坐的生活方式导致北美糖尿病盛行率高，美国在全球人类胰岛素市场占据主导地位。在美国，成本因素是主要问题，因为国内胰岛素製造商赚取了大约一半的收益。美国占了长效胰岛素药物 Lantus 全球销售额的大部分。许多醣尿病药物製造商都将中国视为扩大全球销售的关键市场。 Lantus 是世界上最受欢迎的基础胰岛素，占据美国市场的主导地位。

为什么要购买这份报告？

  • 深刻的分析：获得深入的市场洞察，涵盖主要地区和新兴地区，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透率。
  • 市场驱动因素和未来趋势：探索动态因素和关键市场趋势以及它们将如何影响市场的未来发展。
  • 可行的建议：利用洞察力进行策略决策，在动态环境中开闢新的业务流和收益。
  • 适合广泛的用户：对于新兴企业、研究机构、顾问公司、中小企业和大型企业来说，它都是实用且具有成本效益的。

它有什么用途？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

分析范围

  • 历史资料与预测（2022-2030）
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争对手定位、策略与市场占有率分析
  • 按部门和地区（国家）分類的收益成长和预测分析
  • 公司简介（策略、产品、财务资讯、主要趋势等）

目录

第 1 章 简介

  • 市场概况
  • 市场定义
  • 分析范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第 2 章 分析方法

  • 分析设计
  • 分析过程

第三章执行摘要

  • 主要发现
  • CXO观点

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第 5 章 人类胰岛素市场（依产品类型）

  • 介绍
  • 速效胰岛素
  • 长效胰岛素
  • 结合胰岛素
  • 生物相似药
  • 其他的

6. 人类胰岛素市场依应用划分

  • 介绍
  • 1 型糖尿病
  • 2 型糖尿病

7. 人类胰岛素市场（按分销管道）

  • 介绍
  • 医院
  • 零售药局
  • 其他的

8. 人类胰岛素市场（按地区）

  • 介绍
  • 北美洲
    • 依产品类型
    • 按应用
    • 按分销管道
    • 按国家
  • 南美洲
    • 依产品类型
    • 按应用
    • 按分销管道
    • 按国家
  • 欧洲
    • 依产品类型
    • 按应用
    • 按分销管道
    • 按国家
  • 中东和非洲
    • 依产品类型
    • 按应用
    • 按分销管道
    • 按国家
  • 亚太地区
    • 依产品类型
    • 按应用
    • 按分销管道
    • 按国家

第九章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 企业合併（M&A）、协议、商业合作
  • 竞争仪錶板

第十章 公司简介

  • Eli Lilly and Company
  • Sanofi
  • Novo Nordisk A/S
  • Biocon
  • Boehringer Ingelheim
  • Tonghua Dongbao Pharmaceutical Co.
  • Wockhardt
  • Julphar
  • Gan & Lee Pharmaceuticals
  • Biocon
  • Bioton
  • Novo Nordisk Pharmatech
  • Sigma-Aldrich
  • CDH Fine Chemical
  • BioGems
简介目录
Product Code: KSI061615637

The human insulin market is expected to grow at a CAGR of 3.28%, reaching a market size of US$27,421.71 million in 2030 from US$23,334.45 million in 2025.

Insulin is the hormone that controls sugar levels in the body. Diabetes is a chronic metabolic condition with an abnormal increase in blood glucose or sugar levels. Currently, it has two types. In type 1 diabetes, the pancreatic beta cells are unable to secrete insulin, whereas in type 2, the cells of the body become less sensitive to insulin secretion. With the increasing prevalence of sedentary lifestyles, the incidence of diabetes is anticipated to surge in the insulin market. In addition, favorable reimbursement trends in developed countries are expected to contribute to overall market growth.

Human Insulin Market Drivers

  • Rising cases of diabetes are contributing to the human insulin market growth

Diabetes is a chronic metabolic ailment that has been defined through increased blood glucose levels in the blood hypoglycemia. Humans have human insulin, which is widely used in individualized treatment, insulin replacement in clinical therapy, and specialty treatment to treat and control the disease. However, the demand for insulin is further propelled by the increasing consumption of the drug to treat type 1 diabetes, which controls blood sugar levels and prevents hyperglycemia by providing the essential insulin that does not form in the body. It is used orally and is designed to improve glucose uptake and increase the amount of insulin in the body.

Further, the market is also expanding due to the increasing demand for insulin pump therapy products that provide a continuous flow of insulin all day, mimicking the basal insulin secretion by a healthy pancreas. In addition to that, human insulin is also very important in preventing high or low-glucose shifts in preoperative and critical care environments and, hence, is imperative in lessening surgical complications.

Human Insulin Market Geographical Outlook:

  • North America is witnessing exponential growth during the forecast period.

The high prevalence of diabetes in North America, which is caused by a sedentary lifestyle, has resulted in the United States gaining a stranglehold on the global human insulin market. The cost factor is the biggest concern in the US since domestic insulin producers receive about half of their revenue. The United States accounts for most of the global sales of Lantus, a long-acting insulin. Many diabetes medication manufacturers view the country as a key market to boost global sales. Lantus is the most popular basal insulin worldwide and holds a monopoly on the US market.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The human insulin market is segmented and analyzed as follows:

By Product Type

  • Rapid-Acting Insulin
  • Long-Acting Insulin
  • Combination Insulin
  • Biosimilar
  • Others

By Application

  • Type 1 Diabetes Mellitus
  • Type 2 Diabetes Mellitus

By Distribution Channel

  • Hospitals
  • Retail Pharmacies
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. HUMAN INSULIN MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Rapid-Acting Insulin
  • 5.3. Long-Acting Insulin
  • 5.4. Combination Insulin
  • 5.5. Biosimilar
  • 5.6. Others

6. HUMAN INSULIN MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Type 1 Diabetes Mellitus
  • 6.3. Type 2 Diabetes Mellitus

7. HUMAN INSULIN MARKET BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Retail Pharmacies
  • 7.4. Others

8. HUMAN INSULIN MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Product Type
    • 8.3.2. By Application
    • 8.3.3. By Distribution Channel
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Product Type
    • 8.4.2. By Application
    • 8.4.3. By Distribution Channel
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Italy
      • 8.4.4.5. Spain
      • 8.4.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Product Type
    • 8.5.2. By Application
    • 8.5.3. By Distribution Channel
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Product Type
    • 8.6.2. By Application
    • 8.6.3. By Distribution Channel
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Taiwan
      • 8.6.4.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Eli Lilly and Company
  • 10.2. Sanofi
  • 10.3. Novo Nordisk A/S
  • 10.4. Biocon
  • 10.5. Boehringer Ingelheim
  • 10.6. Tonghua Dongbao Pharmaceutical Co.
  • 10.7. Wockhardt
  • 10.8. Julphar
  • 10.9. Gan & Lee Pharmaceuticals
  • 10.10. Biocon
  • 10.11. Bioton
  • 10.12. Novo Nordisk Pharmatech
  • 10.13. Sigma-Aldrich
  • 10.14. CDH Fine Chemical
  • 10.15. BioGems